Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Coyote Pharmaceuticals to Present at Biotech Showcase™ 2013

MENLO PARK, Calif., Jan. 2, 2013 /PRNewswire/ -- Coyote Pharmaceuticals, Inc., an emerging biopharmaceutical company focused on neurodegenerative diseases, announced today that President and CEO, Hiroaki Serizawa, Ph.D. will present at the Biotech Showcase™ 2013 Conference being held in San Francisco January 7-9, 2013.  Dr. Serizawa will provide an overview of the company's lead compound, CNS-102, which will soon enter clinical development for amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD).

Details of Coyote's presentation are as follows:

Event:


Biotech Showcase 2013 Conference

Date: 


Wednesday, January 9, 2013

Time: 


2:45 pm PST

Location:


Parc 55 Wyndham San Francisco Union Square Hotel

Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present and meet with investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences.  Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week, which is widely viewed as setting the tone for the coming year.

About Coyote Pharmaceuticals:

Coyote Pharmaceuticals, Inc. is an emerging biopharmaceutical company focused on treating neurodegenerative diseases through the modulation of protein folding and transport vital to maintaining cellular homeostasis.  The company's lead drug candidate, CNS-102, is being developed initially to treat amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD).  The orally bioavailable small molecule therapeutic is designed to activate gene expression of a family of proteins – known as heat shock proteins – involved in regulating the folding and transport of other proteins. Heat shock proteins are capable of preventing and repairing the pathophysiological aggregation of other cellular proteins, which are implicated in the etiology of ALS and AD.  For more information on Coyote visit http://www.coyotepharma.com.

For Media & Investors:
Jason Rando / Joshua Drumm, Ph.D.
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jrando@tiberend.com
jdrumm@tiberend.com

 

SOURCE Coyote Pharmaceuticals, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
Yahoo CIO Mike Kail will present a session on DevOps at the 3rd International DevOps Summit, November 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA. Mike brings more than 23 years of IT operations experience with a focus on highly scalable architectures to Y...
Telehealth legislation opened the floodgates for investment in modern communications services and APIs since 2010. WebRTC promises a second revolution. In his session at 2nd WebRTC Summit, Ivelin Ivanov, co-founder of TeleStax, will discuss a real-world example where telephony AP...
The Internet of Things needs an entirely new security model, or does it? Can we save some old and tested controls for the latest emerging and different technology environments? In his session at Internet of @ThingsExpo, Davi Ottenheimer, EMC Senior Director of Trust, will review ...
While great strides have been made relative to the video aspects of remote collaboration, audio technology has basically stagnated. Typically all audio is mixed to a single monaural stream and emanates from a single point, such as a speakerphone or a speaker associated with a vid...
People often ask how Qubell is different from Chef, Puppet, OpenShift, Docker, Heat, Ansible, Mesos, Kubernetes or some other hip product du jour. Like any comparison of apples to oranges, the answer involves a surprisingly deep investigation into botanical conventions, differenc...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE

Breaking Cloud Computing News

NEW YORK, Aug. 28, 2014 /PRNewswire/ -- IBM (NYSE: